Drug
Bgb 3111
Bgb 3111: highest development phase Phase 3, developed by BeiGene. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BeiGene
Trials
| Drug | Phase | Indication |
|---|---|---|
| BGB-3111 NCT03053440 | Phase 3 | Waldenström's Macroglobulinemia |
Latest
No recent events.
Follow Bgb 3111 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.